Company news
Biomea Fusion, Inc. (NASDAQ:BMEA) news
Biomea Fusion, Inc. news releases on 6ix. Latest, Oct 30, 2024: Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness…
Press releases — page 2
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
October 29, 2024
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
October 28, 2024
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
October 20, 2024
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
September 30, 2024
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
September 25, 2024
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
July 30, 2024
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
June 5, 2024
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
May 29, 2024
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
May 1, 2024
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 30, 2024
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
March 31, 2024
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
March 31, 2024
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
January 8, 2024
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
January 7, 2024
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023...
December 10, 2023
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
December 8, 2023
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Re...
December 7, 2023
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
December 4, 2023
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
November 26, 2023
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
November 7, 2023
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
November 1, 2023
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
October 29, 2023
Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
October 16, 2023
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
October 4, 2023
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
September 27, 2023
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
August 30, 2023
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
July 30, 2023
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort...
June 22, 2023
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023
June 19, 2023
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
May 1, 2023
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
April 30, 2023
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
April 18, 2023
Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
April 12, 2023
Biomea Fusion Announces Proposed Public Offering of Common Stock
March 28, 2023
Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock
March 28, 2023
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
March 27, 2023
Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28
March 27, 2023
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
March 22, 2023
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors
January 16, 2023
Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
January 8, 2023
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219
January 3, 2023
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes
December 13, 2022
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
November 6, 2022
Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting
November 2, 2022
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219
October 30, 2022
Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial
October 26, 2022
BMF-219 Enters the Clinic for KRAS Solid Tumors
October 13, 2022
Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes
September 19, 2022
Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting
August 25, 2022
Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights
July 31, 2022